These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25295492)

  • 21. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expectation for new-generation drug eluting stents].
    Saito S
    Nihon Rinsho; 2011 Feb; 69(2):237-9. PubMed ID: 21387669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.
    Auer J; Leitner A; Berent R; Lamm G; Lassnig E; Krennmair G
    Atherosclerosis; 2010 Jun; 210(2):503-9. PubMed ID: 20060973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Influencing 1st and 2nd Generation Drug-Eluting Stent Performance: Understanding the Basic Pharmaceutical Drug-in-Polymer Formulation Factors Contributing to Stent Thrombosis Do We Really Need to Eliminate the Polymer?
    Srdanovic I
    J Pharm Pharm Sci; 2021; 24():435-461. PubMed ID: 34499602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stent thrombosis.
    Gupta S; Gupta MM
    J Assoc Physicians India; 2008 Dec; 56():969-79. PubMed ID: 19322976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stent restenosis and thrombosis: etiology, treatment, and outcomes.
    van Buuren F; Dahm JB; Horskotte D
    Minerva Med; 2012 Dec; 103(6):503-11. PubMed ID: 23229369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future stent drug delivery systems.
    Caixeta A; Abizaid A; Aoki J; Dangas G; Mehran R
    Minerva Cardioangiol; 2008 Feb; 56(1):155-66. PubMed ID: 18432177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.
    Garg P; Cohen DJ; Gaziano T; Mauri L
    J Am Coll Cardiol; 2008 May; 51(19):1844-53. PubMed ID: 18466798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-eluting stents - what should be improved?
    Steffel J; Eberli FR; Lüscher TF; Tanner FC
    Ann Med; 2008; 40(4):242-52. PubMed ID: 18428018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymer coatings and delayed arterial healing following drug-eluting stent implantation.
    Byrne RA; Joner M; Kastrati A
    Minerva Cardioangiol; 2009 Oct; 57(5):567-84. PubMed ID: 19838148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late coronary stent thrombosis.
    Thuesen L; Holm NR
    Minerva Med; 2010 Feb; 101(1):25-33. PubMed ID: 20228718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
    Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eluting combination drugs from stents.
    Thipparaboina R; Khan W; Domb AJ
    Int J Pharm; 2013 Sep; 454(1):4-10. PubMed ID: 23850234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial.
    Yuan F; Chen X; Song X; Wang D; Zhang Z; Li W; Li Z; Li H; Chen X; Huo Y; Wang L; Lu C; Lu Q; Xu B; Li W; Lyu S;
    Chin Med J (Engl); 2014; 127(14):2561-6. PubMed ID: 25043067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New drug-eluting stent platforms to prevent stent thrombosis.
    Kereiakes DJ
    Rev Cardiovasc Med; 2007; 8 Suppl 1():S34-43. PubMed ID: 17401310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
    Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
    Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.